Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.A, non-specified, prohibited in competition. The future 2027 List retains this classification. [1] [2]
2026 and 2027 List, S6.A, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and pharmacology
The reviewed US Vyvanse label identifies lisdexamfetamine as a prodrug of dextroamphetamine. Indications include ADHD in adults and children aged six years and older, and moderate-to-severe binge-eating disorder in adults. It is not labeled for weight loss. [3]
- Product-specific indications are not a worldwide authorization or athlete-clearance statement.
Health concerns
The label carries a boxed warning for abuse, misuse and addiction. It also warns about serious cardiac disease, increases in blood pressure or heart rate, and psychiatric adverse reactions. [3]
- Prescribed treatment and misuse are different contexts; this is not advice to stop needed treatment.
Therapeutic-use process
USADA explains that an ADHD TUE application needs supporting diagnostic and medical-necessity documentation and consideration of reasonable treatment alternatives. A diagnosis alone is not an approved exemption. [4]
- The responsible anti-doping organization and athlete level determine applicable procedures. Do not delay necessary care.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- M8. FDA. Lisdexamfetamine product label, 2026; prodrug identity. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Boxed warning; section 5 · Indications and clinical pharmacology
- E5. USADA. What Do Athletes with ADHD Need to Know About TUEs? ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
ADHD TUE guidance · FDA prescription-stimulant safety communication; USADA ADHD TUE guidance
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.